Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
stones
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "stones" in MCE Product Catalog:
8
8 Publications Verification
Cat. No.: HY-N0190
CAS No.: 29883-15-6
Category:
Alkaloids Other Alkaloids Rosaceae Armeniaca vulgaris Lam. Plants Disease Research Fields Cancer
Target:
5
5
5 Cited Publications
Cat. No.: HY-W009203
CAS No.: 30925-07-6
3
Category:
Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields
Target:
3
3 Cited Publications
Cat. No.: HY-W017386
CAS No.: 3715-31-9
1
1
1 Cited Publications
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .
1
1 Cited Publications
Target:
Research Areas:
CDK5-IN-1 is a potent CDK5 inhibitor with an IC50 less than 10 nM. CDK5-IN-1 is greater than 100-fold more active against CDK5 than CDK2. CDK5-IN-1 is used for kidney diseases research .
Research Areas:
Flurofamide is an effective bacterial urease inhibitor and antibacterial agent. Flurofamide inhibits urease and partially inhibits the chemotactic activity of Helicobacter pylori strain CPY3401. Flurofamide inhibits the growth of Ureaplasma urealyticum. Flurofamide reduces blood ammonia. Flurofamide can be used in the research of infectious urinary stones .
Cat. No.: HY-N9941
CAS No.: 30377-37-8
Target:
Cat. No.: HY-113063R
CAS No.: 1460-34-0
Cat. No.: HY-W088011B
CAS No.: 2836-32-0
Synonyms: Sodium hydroxyacetate, 98%
Cat. No.: HY-W009356
CAS No.: 34760-60-6
Research Areas:
Target:
Aldose Reductase Glutathione Reductase (GR) p38 MAPK ERK JNK Reactive Oxygen Species (ROS) Apoptosis Drug Intermediate
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Glyoxal (40% w/w in water) is an α-oxoaldehyde that inhibits Aldose Reductase, Glutathione Reductase, and NADPH synthase. Glyoxal (40% w/w in water) exhibits cytotoxicity, triggers oxidative stress, induces ROS accumulation, lipid peroxidation, mitochondrial membrane potential collapse, DNA damage, apoptosis, and massive production of advanced glycation end products (AGEs). Glyoxal (40% w/w in water) depletes glutathione and activates MAPK phosphorylation. It has lower toxicity as a fixative than paraformaldehyde (PFA) and serves as a precursor for the synthesis of oxalates and dietary carcinogens. Glyoxal (40% w/w in water) is suitable for research related to calcium oxalate kidney stones, diabetes, atherosclerosis, cardiovascular diseases, retinopathy, and cataracts .
Research Areas:
Benarthin is an orally active Pyroglutamyl peptidase inhibitor, THY1 inhibitor (with a Kd value of 5.13e-08 M) and competitive PGP-1 inhibitor (Ki = 1.2 µM). Benarthin is isolated from the culture broth of Streptomyces xanthophaeus MJ244-SF1. Benarthin disrupts the THY1-SFRP1 interaction, inhibits the activation of the GSK3α/β-β-catenin pathway, and reduces the upregulation of FASLG. Benarthin attenuates urothelial anoikis and reduces cell Apoptosis. Benarthin possesses iron-chelating activity. Benarthin maintains urothelial barrier integrity and blocks the pathological cascade of renal interstitial fibroblasts induced by HAP stimulation. Benarthin can be used in studies related to kidney stones .
Cat. No.: HY-W017386S
CAS No.: 1795037-03-4
Cat. No.: HY-P4890
CAS No.: 1158181-62-4
Target:
RXFP Receptor Reactive Oxygen Species (ROS) Pyroptosis Caspase Interleukin Related TGF-beta/Smad AMPK Apoptosis
Research Areas:
Cat. No.: HY-168434
Target:
Research Areas:
Urease-IN-19 (Compound 3c) is a potent urease inhibitor with an IC50 value of 2.7 µM. Urease-IN-19 is promising for research of kidney stones and stomach ulcers .
Cat. No.: HY-161856
Antifungal agent 106 (Compound Z31) is a benzoic acid derivative and a potential fungicide against Monilinia fructicola. Antifungal agent 106 exhibits antifungal activity with an EC50 value of 11.8 mg/L. It affects hyphal growth by disrupting cell membrane integrity, leading to increased membrane permeability and release of intracellular electrolytes. Antifungal agent 106 can be used in research related to brown rot of stone fruits .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
